Strategic Global Advisors LLC Acquires 285 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Strategic Global Advisors LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 6.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,668 shares of the medical research company’s stock after buying an additional 285 shares during the quarter. Strategic Global Advisors LLC’s holdings in IQVIA were worth $917,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in IQV. Howard Capital Management Inc. increased its position in IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after purchasing an additional 54 shares during the period. Cypress Wealth Services LLC increased its position in shares of IQVIA by 4.8% during the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after buying an additional 57 shares during the period. Harbor Investment Advisory LLC raised its stake in IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock worth $253,000 after buying an additional 58 shares in the last quarter. Magnolia Capital Advisors LLC lifted its holdings in IQVIA by 2.9% in the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company’s stock worth $516,000 after buying an additional 74 shares during the period. Finally, New York Life Investment Management LLC boosted its position in IQVIA by 0.4% during the 4th quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company’s stock valued at $4,537,000 after acquiring an additional 81 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 1.6%

IQV stock opened at $142.66 on Friday. The stock has a market capitalization of $24.68 billion, a P/E ratio of 19.02, a P/E/G ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The business has a fifty day moving average price of $159.83 and a 200-day moving average price of $185.86.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.54 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on IQV shares. Barclays decreased their target price on IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 7th. UBS Group decreased their price objective on IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Hsbc Global Res cut shares of IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $230.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.